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Abstract
Background: The urokinase plasminogen activation (uPA) system is a crucial pathway for tumour invasion
and establishment of metastasis. Although there is good evidence that uPA system expression is a clinically
relevant biomarker in some solid tumours, its role in gastroesophageal cancer is uncertain. Results: We
identified 22 studies encompassing 1966 patients which fulfilled the inclusion criteria. uPA, uPAR, or PAI-1
expression is significantly associated with high risk clinicopathological features. High uPA expression is
associated with a shorter RFS (HR 1.90 95% 1.16-3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74-2.80, p <
0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI 1.82-2.69, p < 0.0001). High
PAI-1 expression is associated with shorter RFS (HR 1.96 96% CI 1.07-3.58, p = 0.03) and OS (HR 1.84
95%CI 1.28-2.64, p < 0.0001). There was no significant association between PAI-2 expression and OS (HR
0.97 95%CI 0.48-1.94, p < 0.92) although data was limited. Materials and Methods: We undertook a
systematic review evaluating expression of uPA, urokinase plasminogen activator receptor (uPAR),
plasminogen activator inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/
SerpinB2) on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas. We
performed a meta-analysis of clinicopathological associations, overall survival (OS) and recurrence free
survival (RFS). Conclusions: We conclude that the uPA system is a clinically relevant biomarker in primary
gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1 associated with higher risk disease
and poorer prognosis. This also highlights the potential utility of the uPA system as a therapeutic target for
improved treatment strategies.
Disciplines
Medicine and Health Sciences
Publication Details
Brungs, D., Chen, J., Aghmesheh, M., Vine, K. L., Becker, T. M., Carolan, M. G. & Ranson, M. (2017). The
urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Oncotarget, 8 (14), 23099-23109.
Authors
Daniel Brungs, Julia Chen, Morteza Aghmesheh, Kara L. Vine, Therese M. Becker, Martin G. Carolan, and
Marie Ranson
This journal article is available at Research Online: http://ro.uow.edu.au/ihmri/1055
Oncotarget23099www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 14), pp: 23099-23109
The urokinase plasminogen activation system in gastroesophageal 
cancer: A systematic review and meta-analysis
Daniel Brungs1,2,3,4, Julia Chen5, Morteza Aghmesheh1,3,4, Kara L. Vine1,2,4, Therese 
M. Becker4,6,7,8, Martin G. Carolan1,3,4, Marie Ranson1,2,4
1Illawarra Health and Medical Research Institute, University of Wollongong, Wollongong, Australia
2School of Biological Sciences, University of Wollongong, Wollongong, Australia
3Illawarra Cancer Centre, Wollongong Hospital, Wollongong, Australia 
4CONCERT-Translational Cancer Research Centre, New South Wales, Australia
5St George Cancer Centre, St George Hospital, Sydney, Australia
6Ingham Institute for Applied Medical Research, Liverpool Hospital, Australia
7School of Medicine, University of Western Sydney, Liverpool, Australia
8South Western Medical School, University of New South Wales, Liverpool, Australia
Correspondence to: Daniel Brungs, email: Daniel.brungs@health.nsw.gov.au
Keywords: stomach neoplasms, gastrointestinal neoplasms, urokinase-type plasminogen activator, urokinase plasminogen 
activator 
Received: November 30, 2016    Accepted: February 07, 2017    Published: February 18, 2017
ABSTRACT
Background: The urokinase plasminogen activation (uPA) system is a crucial 
pathway for tumour invasion and establishment of metastasis. Although there is good 
evidence that uPA system expression is a clinically relevant biomarker in some solid 
tumours, its role in gastroesophageal cancer is uncertain. 
Results: We identified 22 studies encompassing 1966 patients which fulfilled 
the inclusion criteria. uPA, uPAR, or PAI-1 expression is significantly associated 
with high risk clinicopathological features. High uPA expression is associated with a 
shorter RFS (HR 1.90 95% 1.16–3.11, p = 0.01) and OS (HR 2.21 95% CI 1.74–2.80, 
p < 0.0001). High uPAR expression is associated with poorer OS (HR 2.21 95%CI 
1.82–2.69, p < 0.0001). High PAI-1 expression is associated with shorter RFS (HR 
1.96 96% CI 1.07–3.58, p = 0.03) and OS (HR 1.84 95%CI 1.28–2.64, p < 0.0001). 
There was no significant association between PAI-2 expression and OS (HR 0.97 
95%CI 0.48–1.94, p < 0.92) although data was limited. 
Materials and Methods: We undertook a systematic review evaluating expression 
of uPA, urokinase plasminogen activator receptor (uPAR), plasminogen activator 
inhibitor-1 (PAI-1/SerpinE1) and plasminogen activator inhibitor-2 (PAI-2/SerpinB2) 
on primary oesophageal, gastro-oesophageal junction, and gastric adenocarcinomas. 
We performed a meta-analysis of clinicopathological associations, overall survival 
(OS) and recurrence free survival (RFS). 
Conclusions: We conclude that the uPA system is a clinically relevant biomarker 
in primary gastroesophageal cancer, with higher expression of uPA, uPAR and PAI-1  
associated with higher risk disease and poorer prognosis. This also highlights the 





Gastroesophageal cancer is a common and lethal 
malignancy, marked by modest response to systemic 
therapies [1]. A deeper understanding of molecular events 
characterising carcinogenesis, invasion, progression and 
metastasis is central for the development of novel therapies.
The uPA system
A key process in the development and progression 
of cancer, including establishment of metastatic disease, 
is the invasion of malignant cells into normal tissue. The 
plasminogen activation system, particularly the urokinase-
type plasminogen activator (uPA) system, is critical for 
tumour-associated proteolysis to breakdown extracellular 
matrix (ECM) and basement membranes barriers [2]. The 
uPA system has a defined role in tissue degradation and 
extravascular fibrinolysis, and is responsible for most of 
the activated plasminogen associated with cancer invasion 
and metastasis [2, 3] (Figure 1).
The uPA protein is secreted as a zymogen and 
activated on high affinity binding to its specific cell 
surface receptor uPAR. Once activated, uPA catalyses the 
activation of co-localised plasminogen to plasmin, which 
in turn directly degrades components of the ECM, and 
promotes further degradation and tissue remodelling by 
activating pro-metalloproteinases and by releasing, thus 
activating, latent growth factors from the ECM [4]. 
The uPA receptor (uPAR) is anchored to the plasma 
membrane, localising the uPA system to the cell surface 
[5]. High expression of uPAR on the invasive front of 
tumours facilitates invasion and other roles in cellular 
migration and angiogenesis [6]. uPAR expression may 
be a suitable marker for the onset of invasion of both 
gastro-intestinal and breast cancer as it is expressed only 
on invasive carcinomas, not premalignant states such as 
Barrett’s oesophagus [7].
Urokinase-type plasminogen activator is efficiently 
inhibited by two subtypes of serpin (serine proteinase 
inhibitor) family members, plasminogen activator 
inhibitor-1 (PAI-1/SerpinE1) and –2 (PAI-2 /SerpinB2). 
Both form a covalent complex with uPA/uPAR leading 
to internalisation of the entire complex [8] . Although 
believed to have a physiological role as an inhibitor of 
the uPA system, PAI-1 has a paradoxical protumourgenic 
role, increasing tumour invasion and angiogenesis, and 
correlated with poor prognosis [9]. The role of PAI-2 in 
cancer is less clear. Although both PAIs mediate uPA/
uPAR endocytosis, the uPA-PAI-2 complex interacts with 
endocytosis receptors with different binding kinetics to 
those of uPA:PAI-1 and without stimulating intracellular 
signalling events over and above that of uPA binding to 
uPAR [10]. 
While the uPA system is expressed on both cancer 
cells and the supporting stroma, higher expression is 
seen on tumour cells, and is postulated that the tumour 
cell specific uPA/uPAR explains the aggressive biology 
exhibited by these cancers, and is more relevant for 
prognostic outcomes [11–14].  Expression of the uPA 
system has been shown to be an important prognostic 
marker in a variety of cancers including breast cancer 
Figure 1: The uPA system. Schematic representation of the urokinase plasminogen activation (uPA) system. The membrane bound 
urokinase receptor (uPAR) binds circulating inactive pro-uPA, facilitating the activation of pro-uPA to uPA which subsequently converts 
co-localised plasminogen to plasmin that can directly degrade components of the extracellular matrix (ECM) and activate pro-matrix 
metalloproteases (MMP) to further break down ECM. Plasminogen activator inhibitors 1 or 2 (PAI-1, PAI-2) are efficient endogenous 
inhibitors of uPA.
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[15], lung cancer [16], and colorectal cancer [17], with the 
combination of uPA and PAI-1 expression recommended 
to be incorporated into routine clinical care of node 
negative breast cancer [18]. 
In this study we aim to perform a comprehensive 
systematic review of expression of the uPA system 
encompassing uPA, uPAR, PAI-1, and PAI-2 in primary, 
resectable gastro-oesophageal cancer, and undertake 
meta-analyses of prognostic outcomes (recurrence free 
survival and overall survival), and association with 
relevant clinicopathological variables. To the best of our 
knowledge, this is the first meta-analysis to examine and 
compare the expression of these key components of uPA 
system in primary gastro-oesophageal cancer.
RESULTS
Included studies
The trial flow is provided in Figure 2. We identified 
267 reports matching criteria for inclusion in the study, 
of which 109 were selected for abstract review, and 60 
subsequently for full text review. Forty one studies 
(including 2689 patients) fulfilled criteria for inclusion 
in the systematic review, with 22 studies (1966 patients) 
providing sufficient data for inclusion in the formal 
quantitative meta-analysis: 19 studies were excluded 
for the following reasons: 12 studies did not examine 
prognostic or clinicopathological associations, 3 reports 
were matched case control studies, and 4 studies reported 
insufficient published data to derive a HR.
The characteristics of the included studies are 
summarized in Supplementary Table 1. Eighteen studies 
evaluated uPA system expression in gastric cancer (1732 
patients), one study included oesophageal, junctional and 
gastric cancers (39 patients), and two studies examined 
oesophageal cancer only (105 patients). Expression of the 
uPA system was assessed using immunohistochemistry (IHC, 
12 studies, 1273 patients), enzyme-linked immunosorbent 
assay (ELISA, 5 studies, 344 patients), reverse transcription 
polymerase chain reaction (RT-PCR, 3 studies, 153 patients), 
or in-situ hybridisation (ISH, one study, 105 patients). 
Hazard ratios directly extracted for 3 studies 
[7, 11, 22]. The multivariate HR was used when univariate 
value was not provided [22]. When only subgroup outcome 
data (tumour core or peripheral zone) were available, the 
results for peripheral “invasion” zone were used [7, 11]. 
Hazard ratios were estimated for the remaining studies 
using published data. 4 studies reported a “non-statistically 
significant OS” result for uPA system expression, but did not 
publish sufficient data for inclusion in meta-analysis [23–26]. 
Bias risk
The risk of bias summary is summarized in Figure 3. 
Only 4 studies [22, 27–29] were deemed low risk in all bias 
domains. Fourteen studies did not clearly define the study 
population [7, 12, 13, 30–40] and 11 studies did not report 
completeness of followup [7, 12, 13, 30–33, 36, 38, 39, 41]. 
Most studies adequately reported method of measurement of 
the uPA system, although 5 studies did not report whether 
there was a second independent reviewer or blinding to 
clinical information [13, 35, 39, 40, 42]. The followup 
protocol was underreported in 14 studies [7, 11–13, 30–
36, 38–40], although this is unlikely to bias the results for 
overall survival analyses. Most studies did not report details 
of the surgical, medical, or radiation treatments received by 
patients, and were Urokinase plasminogen activator (uPA). 
Urokinase plasminogen activator (uPA)
uPA expression rates
Expression of uPA was evaluated in 13 studies (1254 
patients). The mean expression of uPA was 52.8%, but had 
a large range (from 23% to 91%). There was no significant 
difference in mean expression for IHC (60.7%) and ELISA 
(45.6%) (p = 0.10).
uPA and clinicopathological associations
uPA expression is significantly associated with poorer 
clinicopathological features in resected gastroesophageal 
cancer including: Advanced T stage (T3/4 vs T1/2) (OR 
2.79 95% CI 1.80–4.32, p < 0.0001), nodal metastases 
(OR 2.30 95% CI 1.63–3.51, p < 0.0001), liver 
metastases (OR 6.77 95% CI 2.70–16.96, p < 0.0001), 
peritoneal metastases(OR 2.09 95% CI 1.29–3.36, p = 
0.003), lymphatic invasion (OR 2.28 95% CI 1.31–3.97, 
p = 0.0003), and vascular invasion (OR = 2.43 95% 
CI 1.53–3.86, p = 0.0002) (5 studies, 522 patients, 
Supplementary Figure 1). There is no significant association 
with histology (poorly differentiated vs well differentiated).
uPA expression and prognosis
uPA expression was significantly associated with 
a worse RFS (3 studies, 467 participants, HR 1.90 95% 
1.16–3.11, p = 0.01) (see Supplementary Figure 2). There was 
no significant difference in RFS seen between studies using 
IHC (HR 1.77) or ELISA (HR 2.36) to assess uPA expression 
(test for subgroup differences Chi2 = 0.37, p = 0.54).
uPA expression is significantly associated with 
poorer OS (12 studies, 1094 participants, HR 2.21 95% 
CI 1.74–2.80, p < 0.0001) (see Figure 4). There was no 
significant difference in OS between studies which used 
IHC (HR 1.94) or ELISA (HR = 2.99) to assess uPA 
expression (p = 0.38). Sensitivity analysis showed similar 
results when analysis was restricted to gastric cancer only 
(HR 2.07, p < 0.00001). 
Urokinase plasminogen activator receptor (uPAR) 
uPAR expression rates
Twelve studies (1127 patients) evaluated uPAR 
expression, with mean uPAR expression of 56.8% (range 
Oncotarget23102www.impactjournals.com/oncotarget
14–90%), with similar mean expressions seen in IHC 
(56.8%) and ELISA/RT-PCR (56.7%).
uPAR expression and clinicopathological associations
uPAR expression on primary resected 
gastroesophageal cancer is significantly associated with 
poorer clinicopathological features including: advanced 
TMN stage (stage III/IV vs I/II, OR 3.41 91% CI 1.55–7.53, 
p = 0.002), advanced T stage (OR 2.33 95% CI 1.53 
to 3.56, p < 0.0001), nodal metastases (OR 2.52 95% 
CI 1.70–3.72, p < 0.0001), liver metastases (OR 2.53 95% 
CI 1.25–5.13, p = 0.010), peritoneal metastases (OR 3.15 
95% CI 1.87–5.28, p < 0.0001), lymphatic invasion 
(OR 2.82 95% CI 1.74–4.59, p < 0.0001) and vascular 
invasion (OR 3.85 95% CI 2.53–5.88, p < 0.0001) (six 
studies, 589 patients, Supplementary Figure 3). There is 
no significant association seen with histology (p = 0.6). 
uPAR expression and prognosis
Only one study provided data for uPAR expression 
and RFS [42], showing a shorter RFS with uPAR 
expression (203 patients, HR 2.69, p = 0.03).
uPAR expression is associated with poorer OS 
(11 studies, 1036 patients, HR 2.19 95% CI 1.80–2.66, 
p < 0.0001) (Figure 5). There was no significant difference 
in OS seen between studies which used IHC (HR 2.13), 
ISH (HR 2.34), ELISA (HR 2.19), or RT-PCR (2.66) to 
assess uPAR expression (p = 0.96). 
Plasminogen activator inhibitor-1 (PAI-1)
PAI-1 expression rate
Twelve studies (1031 patients) examined PAI-1 
expression. Mean PAI-1 expression was 53.3%, with no 
Figure 2: Study selection flow diagram. HR –hazard ratio; OS–overall survival; RFS–recurrence free survival.
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statically significant difference in expression between IHC 
(61.8%) and RT-PCR/ELISA (44.7%) (p = 0.1).
PAI-1 expression and clinicopathological variables
PAI-1 expression on primary resected gastroesophageal 
cancer is significantly associated with poorer 
clinicopathological features including: advanced T stage (OR 
2.59 95% CI 1.61 to 4.18,  p < 0.0001), nodal metastases (OR 
2.03 95% CI 1.27–3.22, p < 0.003), lymphatic invasion (OR 
2.09 95% CI 1.31–3.34, p < 0.004) and vascular invasion 
(OR 1.90 95% CI 1.20–3.03, p < 0.007) (three studies, 317 
patients, Supplementary Figure 4). There was no significant 
association of PAI-1 expression with presence of liver 
metastases (OR 0.52, p = 0.18), peritoneal metastases (OR 
1.38, p = 0.31), or histology (OR 0.93, p = 0.74). 
PAI-1 expression and prognosis
PAI-1 expression is associated with shorter RFS 
(3 studies, 467 patients, HR 1.96 96% CI 1.07–3.58, p = 
0.03) (Supplementary Figure 5). There was no significant 
difference in RFS between studies which used IHC or 
ELISA to detect PAI-1 expression (p = 0.86)
PAI-1 expression is significantly associated with a 
shorter OS (10 studies, 839 participants, HR 1.84 95%CI 
1.28–2.64, p < 0.0001, Figure 6). Pre-specified subgroup 
analysis showed a significant difference between studies 
which assessed PAI-1 expression using IHC (HR 1.20, 
p = 0.47) and ELISA (HR 2.94, p < 0.0001) or RT-PCR 
(HR 2.83, p < 0.0001) (p = 0.02). 
Plasminogen activator inhibitor-2 (PAI-2)
PAI-2 expression rate
Two studies (145 participants) assessed PAI-2 
expression (all using IHC) (refer to Supplementary 
Table 1). Mean expression was 57.5%. 
PAI-2 expression and clinicopathological variables
There were no studies with sufficient data analyzing 
PAI-2 expression and clinicopathological variables for 
inclusion in the meta-analysis. 
PAI-2 expression and prognosis
No studies published data on PAI-2 expression 
and RFS. There was no significant association of PAI-2 
expression and OS (2 studies, 145 participants, HR 0.97 
95%CI 0.48–1.94, p < 0.92, Supplementary Figure 6). 
Publication bias
Examination of the funnel plots for the OS analysis 
for uPA, uPAR and PAI-1 showed asymmetrical plots for 
all analyses, suggesting absence of smaller negative trials 
(example plot for uPA provided in Supplementary Figure 7). 
Figure 3: Risk of bias summary. For each bias domain: green = “low risk” means that sufficient data was available to allow assessment 
of quality and fulfilled criteria for each domain, and accordingly is deemed low risk of bias. Orange = “unclear risk” means that insufficient 
data was presented to adequately assess the quality of the domain and accordingly the study has potentially high risk of bias. There were 
no studies deemed high risk of bias. 
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DISCUSSION
This meta-analysis confirms the clinical utility of the 
uPA system as a biomarker in resected gastro-oesophageal 
adenocarcinoma. 
There is good evidence that high expression of 
uPA, uPAR, and PAI-1 is associated with most high 
risk clinicopathological features, including advanced 
T stage, presence of nodal and distant metastases, and 
lymphovascular invasion, in primary gastro-oesophageal 
adenocarcinoma. This supports the central role of the uPA 
system in tumour invasion and metastasis. In contrast, 
there was no significant association of expression found 
with poorly differentiated histology, consistent with 
previously published work which shows that epithelial cell 
uPA system expression is higher in malignant than benign 
tissue, but decreases as tumour becomes more poorly 
differentiated, with a corresponding increase in stromal 
expression [43]. 
We also demonstrated that uPA, uPAR, and PAI-1 
expression is associated with poorer prognosis in resected 
gastro-oesophageal cancer, with both a shorter RFS and 
OS in tumours which expressed these markers. However 
this result should be interpreted with caution due to the 
following important limitations in our study. 
Firstly, only four of the included studies were 
deemed low risk for all bias domains as assessed by the 
QUIPS tool. In particular, most studies did not report 
the treatments patients received which is an important 
potential source of confounding for RFS and OS analyses. 
Additionally, tumours with higher risk clinicopathologic 
features could reasonably be expected to be more likely 
to have received neoadjuvant treatment prior to surgery, 
which may in turn have impacted on the expression of the 
uPA system. Despite this, it should be noted that similar 
results were seen in studies deemed low and high risk of 
study confounding, and heterogeneity was low in both 
the uPA and uPAR OS meta-analyses (I2 = 31% and 0% 
respectively, see Figures 4 and 5). 
Secondly, there is evidence of underreporting of non-
significant results. This is demonstrated by both the funnel 
plot, as well the selective reporting of only statistically 
positive findings from included studies. This important bias 
will cause an overestimation of the effect of expression. 
Thirdly, as demonstrated above, tumours that 
expressed uPA, uPAR and PAI-1 had higher risk features, 
Figure 4: Pooled estimate of hazard ratio (HR) for uPA expression and overall survival (OS). Pooled estimate of hazard 
ratio (HR) for overall survival. The square on each bar represents the HR for an individual trial, and the bar shows the 95% confidence 
interval (CI). The diamond represents a pooled estimate with the centre of the diamond giving the HR estimate, and the extremes of the 
diamond representing the 95% CI. 24.
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and would be expected to recur or progress sooner than 
tumours that did not. The apparent difference in prognostic 
outcomes may be due to unequal baseline characteristics 
of the included participants. 
We did not show a significant difference in the 
prognostic outcomes between studies which used a tumour 
cell specific technique (e.g. IHC) compared to whole 
tissue lysates (e.g. RT-PCR, ELISA) for uPA and uPAR. 
This is consistent with other studies which have shown 
correlation between IHC score and median ELISA value, 
and supports the cancer cells as a major source of uPA and 
uPAR expression in the tumour tissue [44]. 
In contrast, there was a significant different in the 
expression methodology subgroups in the analysis for 
PAI-1 and OS (p = 0.02), with a non-significant outcome 
seen in studies using IHC (HR 1.20, p = 0.47), compared 
to significant results with ELISA (HR 2.94, p < 0.0001) 
and RT-PCR (HR 2.83, p = 0.0007). This highlights the 
importance of the stromal production of PAI-1 within the 
tumour microenvironment [9], as only methods that took into 
account both stromal and tumour PAI-1 showed statistically 
significant prognostic outcomes. It has been postulated that 
in contrast to uPAR, fibroblasts and endothelial cells provide 
the major source of PAI-1 within the tumour tissue [45]. It 
is possible that the PAI-1 detected on the tumour cells by 
IHC may be explained by internalization and accumulation 
of stromal produced uPA-PAI-1 complexes mediated by 
tumour uPAR [46]. No IHC studies examined the association 
between stromal PAI-1 expression and prognostic outcomes 
in gastro-oesophageal cancer. 
All IHC study results used in the meta-analysis 
were restricted to tumour cell expression only. Similar to 
other cancers, uPA system expression was highest at the 
invasive front of the tumour [7, 11, 12, 31]. Only four 
Figure 5: Pooled estimate of hazard ratio (HR) for uPAR expression and overall survival (OS).
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studies reported stromal expression of the uPA system 
[7, 11, 12, 42]. Results were conflicting, with only one study 
showing a significant association of OS with macrophage 
uPAR expression on the invading zone at the periphery of 
the tumour [7]. In colorectal cancer, high uPAR expression 
on macrophages in the tumour core, rather than the 
periphery, is an independent predictor of poor prognosis 
[47]. These studies suggest an important supporting role 
of the tumour associated macrophages within the tumour 
microenvironment. The contrasting pattern of high uPAR 
expression (core versus peripheral) may be due to differing 
phenotypes of the subpopulations of tumour preventing (M1 
macrophages) and tumour promoting (M2 macrophages) 
macrophages within the heterogeneous tumour bulk [48] 
. Further work is required to elucidate the biology of the 
stroma in gastrointestinal cancers. 
We were unable to show any significant associations 
with PAI-2 expression with either clinicopathological 
features or prognostic outcomes, as available data was 
much more limited. Similarly only 3 studies examined 
oesophageal cancer, which limits applicability of our results 
to this subgroup. Sensitivity analysis did not show a different 
result when oesophageal cancer was excluded from analysis. 
In conclusion, expression of the uPA system is 
a clinically relevant biomarker in gastroesophageal 
cancer. There is good evidence to support the association 
of uPA, uPAR, and PAI-1 expression and high risk 
clinicopathological features. While we found a statistically 
significant association between uPAR, uPAR and PAI-1 
expression and poorer prognosis, our results are tempered 
by methodical limitations discussed above. Our findings 
also highlight the potential utility of the uPA system as a 
therapeutic target for improved treatment strategies.
MATERIALS AND METHODS
Methods are reported according to Preferred 
Reporting for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines [19].
Study eligibility/selection criteria
We included all studies which examined the 
following components of the urokinase plasminogen 
activation system uPA, uPAR, PAI-1 or PAI-2, in resected 
primary esophageal, gastroesophageal junction, or 
Figure 6: Pooled estimate of hazard ratio (HR) for PAI-1 expression and overall survival (OS).
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gastric adenocarcinomas. Other tumour pathologies were 
excluded. A ll methods of assessing expression, including 
reverse transcription polymerase chain reaction (RT-
PCR), enzyme-linked immunosorbent assay (ELISA), 
in-situ hybridization (ISH), and immunohistochemistry 
(IHC) were included. For inclusion in the meta-
analysis, studies were required to report the association 
of the following outcomes with uPA system expression: 
overall survival (OS), recurrence-free survival (RFS), or 
clinicopathological variables.
Two authors (DB, JC) independently performed the 
search and screened the studies. The primary outcome was 
OS; secondary outcomes were RFS, and correlation of 
clinicopathological variables with uPA system expression. 
Study search strategy
We searched the following databases in February 
2015 for all trials fulfilling the above criteria: Medline 
(1950–present); EMBASE (1966–present); Cochrane 
Central Register of Controlled Trials, and Cochrane 
Database of Systematic Reviews; PubMed. 
To maximize sensitivity the following search terms 
were used: Stomach Neoplasms (MESH) OR Esophageal 
neoplasms (MESH) OR Gastrointestinal neoplasms 
(MESH) OR Gastric cancer.mp OR Gastric carcinoma.
mp OR esophageal cancer.mp OR oesophageal cancer.
mp OR gastroesophageal cancer.mp AND Receptors, 
urokinase plasminogen activator (MESH) OR Urokinase-
type plasminogen activator (MESH) OR Plasminogen 
activator inhibitor 1 (MESH) OR Plasminogen activator 
inhibitor.mp OR PAI-1.mp OR PAI-2.mp OR Urokinase* 
plasminogen.mp OR uPA*.mp. Reference lists of included 
studies and review articles were hand searched. The search 
was restricted to studies published in English. 
Data collection
Study data was independently collected by two 
authors (DB, JC) using standardized electronic data 
collection forms. The following was collected for each 
study: patient number, primary tumour location (gastric/
oesophageal/COJ), cancer stage, treatment received by 
patient; uPA components assessed (uPA, uPAR, PAI- 1, 
PAI-2) and method, patient followup; outcomes (OS 
or RFS), clinicopathological correlations (including 
TMN stage, tumour grade, lymphatic invasion, vascular 
invasion). For studies which used IHC, expression analysis 
was restricted to tumour cells only (stromal expression 
was not included in the meta-analysis).
Assessment of bias within studies
All studies included in the meta-analyses were 
assessed for bias using the Quality In Prognosis Studies 
(QUIPS) tool which assesses for potential sources of bias 
in six domains namely: study participation; study attrition 
and loss to followup; prognostic factor measurement; 
outcome measurement; study confounding; and statistical 
analysis and reporting [20].
Statistical analysis
We extracted the hazard ratio (HR) and their 
95% confidence intervals (CI) for time-to-event 
outcomes including RFS and OS. If both univariate and 
multivariate HR were published the univariate results 
were preferentially used. Where no HR was provided in 
published data, it was estimated from available results or 
Kaplan-Meier survival curves using previously described 
methods [21]. 
HRs were synthesized using the generic inverse 
variance method and a random effect model using 
RevMan5.1 analysis software. Statistical heterogeneity 
was assessed using the I2 statistic. We performed pre-
specified subgroup analysis for overall survival for: 
primary location (gastric or oesophageal), cancer cell 
specific expression (using IHC) compared to whole cell 
lysis (using RT-PCR/ELISA). 
Clinicopathological associations were summarized 
using odds ratios (OR) derived from published results. 
This analysis was limited to studies using IHC, as other 
methods presented expression results as means, rather than 
percentage of patients expressing. Expression rates were 
described with mean and range, and compared using the 
student’s t-test. 
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